PriceTargets.com logo

KalVista Pharmaceuticals - KALV Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $26.63
  • Forecasted Upside: 62.35%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$16.40 As of 12/4/2025 05:00 PM ET
▲ +1.74 (11.87%)

This chart shows the closing price for KALV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New KalVista Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KALV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KALV

Analyst Price Target is $26.63
▲ +62.35% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for KalVista Pharmaceuticals in the last 3 months. The average price target is $26.63, with a high forecast of $30.00 and a low forecast of $20.00. The average price target represents a 62.35% upside from the last price of $16.40.

This chart shows the closing price for KALV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 investment analysts is to moderate buy stock in KalVista Pharmaceuticals. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/4/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00
12/3/2025CowenReiterated RatingBuy ➝ Buy
11/11/2025CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
11/11/2025Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$29.00 ➝ $28.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/12/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00
9/12/2025JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$27.00 ➝ $28.00
7/8/2025JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $27.00
7/8/2025HC WainwrightBoost TargetBuy ➝ Buy$20.00 ➝ $27.00
7/7/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$18.00 ➝ $20.00
4/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
3/26/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
3/26/2025Jones TradingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
1/31/2025Citizens JmpUpgradeStrong-Buy
1/31/2025JMP SecuritiesInitiated CoverageOutperform$19.00
1/7/2025TD CowenInitiated CoverageBuy$30.00
12/18/2024Bank of AmericaInitiated CoverageBuy$22.00
12/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
12/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
12/5/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
10/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
9/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
9/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
8/26/2024Cantor FitzgeraldUpgradeStrong-Buy
7/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
7/12/2024Needham & Company LLCLower TargetBuy ➝ Buy$35.00 ➝ $32.00
6/18/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
5/3/2024HC WainwrightLower TargetBuy ➝ Buy$24.00 ➝ $20.00
5/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00
2/14/2024HC WainwrightBoost TargetBuy ➝ Buy$16.00 ➝ $24.00
2/13/2024Needham & Company LLCBoost TargetBuy ➝ Buy$22.00 ➝ $35.00
9/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$16.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00
4/21/2023Needham & Company LLCReiterated RatingBuy$22.00
4/11/2023Cantor FitzgeraldReiterated RatingOverweight
3/10/2023HC WainwrightReiterated RatingBuy$16.00
3/9/2023Needham & Company LLCReiterated RatingBuy$24.00 ➝ $22.00
2/3/2023Leerink PartnersLower TargetOutperform$30.00 ➝ $20.00
10/6/2022HC WainwrightLower TargetBuy$48.00 ➝ $16.00
10/5/2022Leerink PartnersLower TargetOutperform$45.00 ➝ $30.00
10/4/2022Needham & Company LLCLower TargetBuy$38.00 ➝ $24.00
7/8/2022Leerink PartnersLower TargetOutperform$51.00 ➝ $45.00
7/8/2022Needham & Company LLCLower TargetBuy$42.00 ➝ $38.00
3/11/2022HC WainwrightReiterated RatingBuy$48.00
3/11/2022Needham & Company LLCLower TargetBuy$48.00 ➝ $42.00
3/8/2022Roth CapitalReiterated RatingBuy
12/12/2021Leerink PartnersReiterated RatingBuy$51.00
12/10/2021Needham & Company LLCLower TargetBuy$50.00 ➝ $48.00
9/12/2021Leerink PartnersReiterated RatingBuy$51.00
9/10/2021HC WainwrightReiterated RatingBuy$48.00
7/14/2021HC WainwrightReiterated RatingBuy$48.00
3/16/2021Leerink PartnersReiterated RatingBuy
2/17/2021Roth CapitalBoost TargetBuy$30.00 ➝ $55.00
2/10/2021Leerink PartnersBoost TargetOutperform$39.00 ➝ $51.00
2/10/2021HC WainwrightBoost TargetPositive ➝ Buy$30.00 ➝ $48.00
2/9/2021Jefferies Financial GroupBoost TargetBuy$34.00 ➝ $61.00
2/9/2021Stifel NicolausBoost TargetPositive ➝ Buy$30.00 ➝ $54.00
1/26/2021Needham & Company LLCBoost TargetPositive ➝ Buy$25.00 ➝ $32.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 15 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 8 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/7/2025
  • 15 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 11 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 15 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 18 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 18 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

KalVista Pharmaceuticals logo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $16.40
Low: $14.30
High: $16.80

50 Day Range

MA: $12.21
Low: $10.76
High: $16.40

52 Week Range

Now: $16.40
Low: $7.30
High: $17.28

Volume

2,794,410 shs

Average Volume

1,609,777 shs

Market Capitalization

$829.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of KalVista Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on KalVista Pharmaceuticals in the last year: Bank of America Corporation, Cantor Fitzgerald, Citigroup Inc., Citizens Jmp, Cowen Inc, HC Wainwright, JMP Securities, Jones Trading, Leerink Partners, Needham & Company LLC, TD Cowen, and Weiss Ratings.
View the latest analyst ratings for KALV.

What is the current price target for KalVista Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for KalVista Pharmaceuticals in the last year. Their average twelve-month price target is $26.63, suggesting a possible upside of 62.3%. TD Cowen has the highest price target set, predicting KALV will reach $30.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $20.00 for KalVista Pharmaceuticals in the next year.
View the latest price targets for KALV.

What is the current consensus analyst rating for KalVista Pharmaceuticals?

KalVista Pharmaceuticals currently has 1 sell rating and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KALV.

What other companies compete with KalVista Pharmaceuticals?

Other companies that are similar to KalVista Pharmaceuticals include Catalyst Pharmaceuticals, Edgewise Therapeutics, Nuvation Bio, Apellis Pharmaceuticals and Bausch Health Cos. Learn More about companies similar to KalVista Pharmaceuticals.

How do I contact KalVista Pharmaceuticals' investor relations team?

KalVista Pharmaceuticals' physical mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company's listed phone number is 857-999-0075 and its investor relations email address is [email protected]. The official website for KalVista Pharmaceuticals is www.kalvista.com. Learn More about contacing KalVista Pharmaceuticals investor relations.